ICD-10-CM Tabular Index · Chapter 9 · FY 2026 I67

Other cerebrovascular diseases (I67) ICD-10-CM

The I67 code range covers other cerebrovascular diseases with 21 ICD-10-CM diagnosis codes. 17 of them are billable and valid for claim submission in fiscal year 2026, and the category headers group them but cannot themselves be billed.

✓ Built from the official CMS FY 2026 datasetEffective Oct 1, 2025 – Sep 30, 2026
21
Diagnosis Codes
17
Billable Codes
I67
Code Range
I60–I69
Parent Section

Type 1 Excludes

A type 1 excludes note is a pure excludes note. It means "NOT CODED HERE!" An Excludes1 note indicates that the code excluded should never be used at the same time as the code above the Excludes1 note. An Excludes1 is used when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.

Type 2 Excludes

A type 2 excludes note represents "Not included here". An excludes2 note indicates that the condition excluded is not part of the condition represented by the code, but a patient may have both conditions at the same time. When an Excludes2 note appears under a code, it is acceptable to use both the code and the excluded code together, when appropriate.

ICD-10-CM

Codes in the I67 Range 21 codes · 17 billable

21 of 21 shown
  • I67 Other cerebrovascular diseasesNon-billable
  • I67.0 Dissection of cerebral arteries, nonruptured
  • I67.1 Cerebral aneurysm, nonruptured
  • I67.2 Cerebral atherosclerosis
  • I67.3 Progressive vascular leukoencephalopathy
  • I67.4 Hypertensive encephalopathy
  • I67.5 Moyamoya disease
  • I67.6 Nonpyogenic thrombosis of intracranial venous system
  • I67.7 Cerebral arteritis, not elsewhere classified
  • I67.8 Other specified cerebrovascular diseasesNon-billable
  • I67.81 Acute cerebrovascular insufficiency
  • I67.82 Cerebral ischemia
  • I67.83 Posterior reversible encephalopathy syndrome
  • I67.84 Cerebral vasospasm and vasoconstrictionNon-billable
  • I67.841 Reversible cerebrovascular vasoconstriction syndrome
  • I67.848 Other cerebrovascular vasospasm and vasoconstriction
  • I67.85 Hereditary cerebrovascular diseasesNon-billable
  • I67.850 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
  • I67.858 Other hereditary cerebrovascular disease
  • I67.89 Other cerebrovascular disease
  • I67.9 Cerebrovascular disease, unspecified

Clinical Terms in This Code Range

Definitions from the National Library of Medicine for conditions coded in the I67 range.

Giant Cell Arteritis

A systemic autoimmune disorder that typically affects medium and large ARTERIES, usually leading to occlusive granulomatous vasculitis with transmural infiltrate containing multinucleated GIANT CELLS. The TEMPORAL ARTERY is commonly involved. This disorder appears primarily in people over the age of 50. Symptoms include FEVER; FATIGUE; HEADACHE; visual impairment; pain in the jaw and tongue; and aggravation of pain by cold temperatures. (From Adams et al., Principles of Neurology, 6th ed)

Hypertensive Encephalopathy

Brain dysfunction or damage resulting from sustained MALIGNANT HYPERTENSION. When BLOOD PRESSURE exceeds the limits of cerebral autoregulation, cerebral blood flow is impaired (BRAIN ISCHEMIA). Clinical manifestations include HEADACHE; NAUSEA; VOMITING; SEIZURES; altered mental status (in some cases progressing to COMA); PAPILLEDEMA; and RETINAL HEMORRHAGE.

Intracranial Aneurysm

Abnormal outpouching in the wall of intracranial blood vessels. Most common are the saccular (berry) aneurysms located at branch points in CIRCLE OF WILLIS at the base of the brain. Vessel rupture results in SUBARACHNOID HEMORRHAGE or INTRACRANIAL HEMORRHAGES. Giant aneurysms (>2.5 cm in diameter) may compress adjacent structures, including the OCULOMOTOR NERVE. (From Adams et al., Principles of Neurology, 6th ed, p841)

Moyamoya Disease

A noninflammatory, progressive occlusion of the intracranial CAROTID ARTERIES and the formation of netlike collateral arteries arising from the CIRCLE OF WILLIS. Cerebral angiogram shows the puff-of-smoke (moyamoya) collaterals at the base of the brain. It is characterized by endothelial HYPERPLASIA and FIBROSIS with thickening of arterial walls. This disease primarily affects children but can also occur in adults.

About the I67 Code Range

The ICD-10 code section I67 covers "Other cerebrovascular diseases," including various uncommon or complex conditions affecting brain blood vessels beyond typical strokes. These codes help specify diagnoses like cerebral artery dissections, nonruptured aneurysms, and rare vascular syndromes.

Specifically, I67.0 identifies nonruptured dissections of cerebral arteries, known also as dissecting aneurysms of various brain arteries. I67.1 denotes nonruptured cerebral aneurysms, including conditions like intracranial aneurysm and Berry aneurysm. I67.2 involves cerebral atherosclerosis, a cause of chronic brain blood flow problems. Other codes address progressive white-matter disease (I67.3), hypertensive encephalopathy (I67.4), and Moyamoya disease (I67.5), a rare stenosis of the carotid arteries. Venous thromboses are coded under I67.6, while cerebral arteritis falls under I67.7. Additional codes cover acute and chronic cerebral ischemia, reversible vasoconstriction syndromes, hereditary cerebrovascular disorders, and radiation-induced brain necrosis. This section uniquely helps medical coders precisely classify and document these less common cerebrovascular conditions in medical records and billing.

Questions About This Page

How many billable codes are in the I67 range?

Of the 21 codes in this range, 17 are billable and valid for claim submission from October 1, 2025 through September 30, 2026. Category header codes group them but cannot be reported on claims.

What does the I67 range classify?

The range classifies other cerebrovascular diseases. Each code links to its own reference page with billing status, MS-DRG grouping, coding notes, and clinical information.

Related References

Source: CMS FY 2026 ICD-10-CM Tabular List and order file, effective October 1, 2025 through September 30, 2026.